The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer

The p53/MDM2 interaction has been a well-studied target for new drug design leading to the development of the small molecule inhibitor Nutlin-3. Our objectives were to combine Nutlin-3 with cisplatin (CDDP), a well-known activator of the p53 pathway, in a series of non-small cell lung cancer cell li...

Descripción completa

Detalles Bibliográficos
Autores principales: Deben, Christophe, Wouters, An, de Beeck, Ken Op, van Den Bossche, Jolien, Jacobs, Julie, Zwaenepoel, Karen, Peeters, Marc, Van Meerbeeck, Jan, Lardon, Filip, Rolfo, Christian, Deschoolmeester, Vanessa, Pauwels, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673190/
https://www.ncbi.nlm.nih.gov/pubmed/26125230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673190/
https://www.ncbi.nlm.nih.gov/pubmed/26125230

Ejemplares similares